Potent inhibition of genital herpesvirus infection in goats by cidofovir

[en] Background: Like human herpesvirus 2 (HHV-2) in humans, infection by caprine herpesvirus 1 in goats is associated with genital lesions, and this provides a unique model to study the efficacy and effects of anti-herpetic drugs. Methods: The antiviral activity of cidofovir was assessed in goats infected experimentally, using various therapeutic protocols. Results: Topic administration of cidofovir 1% cream prevented the onset of virus-induced genital lesions and drastically reduced virus shedding. Conclusion: Cidofovir appears to be a very efficient drug for the prevention of genital lesions caused by an alphaherpesvirus.

Disciplines :

Pharmacy, pharmacology & toxicology
Immunology & infectious disease

Author, co-author :

Tempesta, Maria

Camero, Michele

Bellacicco, Anna Lucia

Tarsitano, Elvira

Crescenzo, Giuseppe

Thiry, Julien ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires > Virologie, épidémiologie et pathologie des maladies virales

Martella, Vito

Decaro, Nicola

Elia, Gabriella

Neyts, Johan

Thiry, Etienne ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires > Virologie, épidémiologie et pathologie des maladies virales

Buonavoglia, Canio

Language :

English

Title :

Potent inhibition of genital herpesvirus infection in goats by cidofovir

Publication date :

2007

Journal title :

Antiviral Therapy

ISSN :

1359-6535

eISSN :

2040-2058

Publisher :

Int Medical Press Ltd, London, United Kingdom

Volume :

Issue :

Pages :

977-979

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 04 March 2009

Statistics

Number of views

39 (1 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Corey L, Handsfield HH. GH and public health. J Am Med Assoc 2000; 283:791-794.
Malkin JE. Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 2004; 11 Suppl 1:2A-23A.
Xu F, Stenberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. J Am Med Assoc 2006; 296:964-973
Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries Sex Transm Inf 2007; 83:16-22.
Deback C, Huraux JM. Herpes simplex virus vaccines: perspectives. Revue Méd Inter 2007; 28:16-21.
Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol 2007; 57:238-246.
De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30:115-133.
De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nature Rev Drug Disc 2005; 4:928-940.
Tempesta M, Pratelli A, Normanno G, et al. Experimental intravaginal infection of goats with caprine herpesvirus 1. J Vet Med B 2000; 47:145-151.
Tempesta M, Buonavoglia D, Sagazio P, Pratelli A, Buonavoglia C. Natural reactivation of caprine herpesvirus 1 in latently infected goats. Vet Rec 1998; 143:200.
Tempesta M, Pratelli A, Greco G, Martella V, Buonavoglia C. Detection of caprine herpesvirus 1 (CpHV-1) in the sacral ganglia of latently infected goats by polymerase chain reaction. J Clin Microbiol 1999; 37:1598-1599.
Tempesta M, Camero M, Bellacicco AL, et al. Cidofovir is effective against caprine herpesvirus 1 infection in goats. Antivir Res 2007; 74:138-141.
Buonavoglia C, Tempesta M, Cavalli A, et al. Reactivation of caprine herpesvirus 1 in latently infected goats. Comp Immunol Microbiol Infect Dis 1996; 19:275-281.
Stragier I, Snoeck R, De Clercq E, Van Den Oord JJ, Van Ranst M, De Greef H. Local treatment of HPV-induced skin lesions by cidofovir. J Med Virol 2002; 67:241-245.
Tempesta M, Greco G, Pratelli A, et al. Reactivation of caprine herpesvirus 1 in experimentally infected goats. Vet Rec 2002; 150:116-117.